SABCS 2023 | SURVIVE study: liquid biopsy guided follow-up surveillance in early breast cancer

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, describes plans for the SURVIVE study which is the first large, randomized breast cancer surveillance trial to investigate the potential survival benefit of a liquid biopsy guided follow-up care in intermediate- to high-risk early breast cancer patients. The study is ongoing in Germany and 3500 patients are planned for randomization in a 1:1 ratio to standard vs. liquid biopsy guided intensified follow-up care. The SURVIVE-study is a long-awaited trial in early breast cancer follow-up, based on promising liquid biopsy markers. If successful, the results will lead to a paradigm shift in current follow-up care of intermediate to high-risk early breast cancer survivors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.